Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Outlicenses Products To California Startup, Considers Expanding Model To More Of Its Portfolio

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas Pharma Inc. is trying out a new model, out-licensing three compounds to a startup created specifically to support the development of the products while Astellas retains options to buy back the products. The Japanese pharma is reducing costs for non-priority therapeutic targets, and if successful, may repeat the model for other compounds in its pipeline
Advertisement

Related Content

Astellas Shuts U.S./EU Phase III Diabetes Trial But Resumes Asia Development For Differentiated Markets
Astellas Shuts U.S./EU Phase III Trial But Resumes Asia Development For Differentiated Markets
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
Japan's Mitsui Acquires Stake In India's Arch Pharma For Direct Presence In The "Global Factory"
Boehringer Taking Over Actimis In Structured Buyout
Boehringer Taking Over Actimis In Structured Buyout
Advertisement
UsernamePublicRestriction

Register

SC077812

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel